Literature DB >> 31098918

The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting System.

Monica A Muñoz1, Gerald J Dal Pan2.   

Abstract

Mesh:

Year:  2019        PMID: 31098918     DOI: 10.1007/s40264-019-00834-1

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  3 in total

1.  Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.

Authors:  Lisa Harinstein; Dipti Kalra; Cindy M Kortepeter; Monica A Muñoz; Eileen Wu; Gerald J Dal Pan
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

2.  Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.

Authors:  James R Rogers; Ameet Sarpatwari; Rishi J Desai; Justin M Bohn; Nazleen F Khan; Aaron S Kesselheim; Michael A Fischer; Joshua J Gagne; John G Connolly
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

3.  When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection.

Authors:  Kevin Klein; Joep H G Scholl; Marie L De Bruin; Eugène P van Puijenbroek; Hubert G M Leufkens; Pieter Stolk
Journal:  Clin Pharmacol Ther       Date:  2017-10-25       Impact factor: 6.875

  3 in total
  2 in total

1.  An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.

Authors:  Kathryn Marwitz; S Christopher Jones; Cindy M Kortepeter; Gerald J Dal Pan; Monica A Muñoz
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

2.  A descriptive analysis of concomitant opioid and benzodiazepine medication use and associated adverse drug events in United States adults between 2009 and 2018.

Authors:  Kathryn K Marwitz; Marwa Noureldin
Journal:  Explor Res Clin Soc Pharm       Date:  2022-03-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.